 |
Dott. M. M. Ciammaichella
Dirigente Medico
SC Medicina Interna I° per l'Urgenza
(Direttore: Dott. G. Cerqua)
A.C.O. S. Giovanni – Addolorata, Roma, Italia
HYPERNATREMIA
.
INTRODUCTION
CLINICAL
WORKUP
TREATMENT
MEDICATION
FOLLOW-UP
MISCELLANEOUS
BIBLIOGRAPHY
.
INTRODUCTION
Background: Hypernatremia, defined as a serum sodium > 145 mEq/L, is a common electrolyte problem, especially in elderly and hospitalized patients. Normally, the serum sodium and serum tonicity is maintained within a relatively narrow range. This occurs via stimulation of thirst and control of renal excretion of water by vasopressin release.
Overall, an intact thirst mechanism with free access to water is the most important factor in preventing hypernatremia.
Given the high mortality (generally reported > 50% in elderly patients) associated with this condition, it is important for the emergency physician to recognize, understand and be able to treat this condition.
Hypertonicity is defined as increased solutes in extracellular fluid (ECF) which do not cross cell membranes (e.g., sodium, mannitol, glucose).
Hyperosmolarity is defined as increased solutes (e.g., urea, alcohol) which freely cross all membranes or glucose which does not cross cell mambranes. It may be present without hypertonicity.
Pathophysiology: Disorders of sodium are the result of a problem with water balance.
Water homeostasis results from the balance between water intake and the combined loss of water from renal excreation, respiratory, skin and gastrointestinal tract sources. Under normal conditions, water intake and losses are matched.
Thirst is physiologically regulated, responding to changes in serum tonicity and extracellular volume. Overall, thirst is the major defense against hypertonicity and in those patients that develop hypernatremia, the major defect is usually impairment of water intake. Even in patients with diabetes insipidus (a condition in which renal water excretion is maximal, up to 20 L/day), dehydration will not occur if the patient has free access to water.
Hypertonicity is a condition in which cells are dehydrated as a result of water loss or an increase in serum osmolarity. The central nervous system is the most important organ system affected by hypernatremia and accounts for most of the symptoms.
Initially the brain cells shrink from water extraction. This is immediately offset by active transport of electrolytes (Na+ and K+) across the neuronal cell membrane. After one hour of hypernatremia, the neurons begin to generate intracellular organic solutes that protect the neurons from structural damage and restore cell volume. This, however, leads to ineffective functioning of the neurons.
This protective mechanism must be kept in mind when treating a patient with hypernatremia. Otherwise, water replacement may proceed at a rate that does not allow for excretion of accumulated solutes, leading to cerebral edema.
Frequency:
- In the US: Approximately 0.3 to 1% of hospitalized patients; 60 to 80% of these patients develop hypernatremia after hospital admission
Mortality/Morbidity: Overall mortality rates are between 40 and 50%. The highest are among the elderly.
- Most deaths are due to the underlying disease process, not the hypernatremia. However, delays in or inadequate treatment of hypernatremia will increase mortality.
- In hospitalized patients, persistent hypernatremia and protracted hypotension has been associated with a dismal prognosis.
Sex: Male = Female
Age:
- Patients who present to the hospital with hypernatremia are older that the general population and typically come from a nursing home.
- Older patients have a blunted response to hypernatremia and a decreased renal concentrating ability.
- In the setting of increased water losses, this can lead to hypernatremia.
CLINICALPATHOPHYSIOLOGY
History:
- The severity of symptoms usually correlate with the extent of the hyperosmolarity.
Physical: When hypernatremia is a result of hypotonic fluid losses, significant hypovolemia may be present, accounting for the clinical manifestations of hypovolemic shock (i.e., tachycardia, orthostasis and hypotension).
Assessment of overall fluid status is important in determination of the exact cause of the hypernatremia.
- Muscle twitching Delirium Coma
Causes:
- Hypovolemic Hypernatremia (Water Deficit > Sodium Deficit):
- Extrarenal Losses:
Diarrhea, vomiting, fistulas, significant burns
- Renal Losses:
Osmotic diuresis, diuretics, postobstruction, intrinsic renal disease
- Hypervolemic Hypernatremia (Sodium Gains > Water Gains):
- Hypertonic saline, NaHCO3 administration, accidental salt ingestion
- Mineralocorticoid excess (Cushing syndrome)
- Increased insensible loss (e.g., hyperventilation)
- Renal Losses:
Central diabetes insipidus, nephrogenic diabetes insipidus
- These patients appear euvolemic because most of the free water loss is from the intracellular and interstitial spaces, with only 8% occurring from the intravascular space. This typically does not produce symptoms unless the serum sodium is > 160 to 170 mEq/L.
- Adipsic hyponatremia is secondary to decreased thrist
- Primary hypodipsia, due to destruction of the thirst centers in the hypothalamus, is a rare cause.
- Essential hypernatremia results from an upward setting of the osmotic threshold for thirst and vasopressin release.
- Adipsic Dypernatremia Differential Diagnosis:
Vascular: (15%) Anterior Communicating Artery (aneurysm, ligation), intrahypothalmic hemorrhage, internal carotid artery ligation
Neoplastic: (50%) Primary, metastatic
Granuloma: (20%) Histocytosis X, sarcoidosis
Miscellaneous: (15%) Hydrocepahlus, ventricular cyst, trauma, idiopathic
- Central Diabetes Insipidus Differential Diagnosis:
Primary or idiopathic (most common cause)
Nonfamilial form, congenital form
Secondary: Head trauma, posthypophysectomy, supracellar or intracellar tumors, granulomas (sarcoidosis, Wegener's granulomatosis, tuberculosis, syphilis), histocytosis (eosinophilc granuloma), infectious (encephalitis, meningits, Guillain-Barre syndrome), vascular (cerebral anerysm, thrombosis, hemorrhage, Sheehan's syndrome)
- Nephrogenic Diabetes Insipidus Differential Diagnosis:
Advanced renal disease (insterstitial disease)
Electrolyte disturbances: hypokalemia, hypercalcemia
Systemic Diseases:
Sickle cell disease, Sjogren's syndrome, amyloidosis, Fanconi sydrome, sarcoidosis, renal
tubular acidosis, light chain nephropathy
Dietary disturbances: excessive water intake, decreased salt intake, decreased protein intake
Drugs: Lithium, democlocycline, colchicine, vinblastin, amphotericin B, gentamicin, furosemide, angiographic dyes, osmotic diuretics
Miscellaneous: Postobstructive diuresis, diuretic phase of acute renal failure, osmotic diuresis, paroxysmal hypertension

WORKUP
Lab Studies:
- A low urine sodium and a high urine osmolality is consistent with extrarenal hypotonic fluid losses.
- Isotonic urine osmolality can be seen with diuretics, osmotic diuresis or salt wasting.
- If the serum sodium is > 150-170 mEq/L, it is usually dehydration
- If the serum sodium is > 170 mEq/L is is usually diabetes insipidus
- If the serum sodium is > 190 mEq/L it is usually chronic salt ingestion
- The urine osmolality is less than the serum osmolality.
- The urine sodium is usually low.
- The blood sugar is elevated.
- Increased urine osmolality
- Increased urine osmolality
- Increased urine osmolality
Imaging Studies:
- Head CT Scan or Magnetic Resonance Imaging (MRI):
- Traction on the dural veins and sinuses can lead to intracranial hemorrage.
- May indicate a central cause for the hypernatremia
- To rule out craniopharyngioma, tumor or meian cleft syndrome
Other Tests:
- Water Deprivation Test:
With diabetes insipidus, the urine osmolality does not increase with hypernatremia.
- Antidiuretic Hormone (ADH) Stimulation:
With nephrogenic diabetes insipidus, the urine osmolality does not increase after ADH of DDAVP (Desmopressin).
TREATMENT
Prehospital Care: Standard supportive attention to the ABC's.
Emergency Department Care: Restoration of normal serum tonicity is the main goal in treating hypernatremia. Prior to calculating fluid deficits, the patient's extracellular fluid volume must first be determined. This may ultimately involve the use of Swan - Ganz Catheters. However, a careful physician examination will usually be enough to guide the initial management of the patient.
- Hypovolemic patients should first be stabilized with normal saline prior to correcting free fluid deficits.
Hypervolemic patients require removal of excess sodium, which can be accomplished by a combination of diuretics and D5W infusion but may require dialysis in the face of ARF.
Euvolemic patients can be treated with D5W infusions to correct free fluid deficits as calculated below:
- Fluid Deficits:
Free H2O deficit = Body wt (Kg) x %Total body water x (plasma Na/140 1)
% Total Body Water should be as follows:
0.5 for young women
0.6 for young men
0.4 for elderly women
0.5 for elderly men
- Examples:
A serum sodium (Na) of 155 in a 60 kg young man results in a fluid deficit of
60 x 0.6 x (155/140 1) or 3.86 L
A serum sodium of 155 in a 60 kg elderly female results in a fluid deficit of
60 x 0.4 x (155/140 1) or 2.57 L
- Replace deficits over 48 hours, allowing for no more than 1 2 mEq/hr reduction in serum sodium.
- Replacement fluid should be D5W or hypotonic saline (1/4 or 1/2 NS)
- Measure serum electrolytes frequently, initially every two hours.
- Search for and treat the underlying medical condition.
- Replace ongoing fluid losses.
- Dialysis, particularly with serum sodium > 220 mEq/L
Consultations:
- Patients with renal failure may require dialysis to help correct sodium and fluid balance.
MEDICATION
The maintenance of adequate fluid intake is the most important therapy for all causes of diabetes insipidus (DI) that can result in hypernatremia. Hormonal and pharmacologic therapy have to be tailored for the specific causes of DI (e.g., central Vs. nephrogenic).
Central DI is treated with replacement therapy of antidiurtic hormone. The therapy for nephrogenic DI focuses on reducing urine volume, by combinations of salt restriction, thiazide Diuretics, and prostaglandin synthetase inhibitors.
Drug Category: Antidiuretic Hormone (ADH) Replacement Therapy - It is used to reduce diuresis.
Drug Name
|
Vasopressin - Has vasopressor and antidiuretic hormone (ADH) activity. It increases water resorption at the distal renal tubular epithelium (ADH effect) and promotes smooth muscle contraction throughout the vascular bed of the renal tubular epithelium (vasopressor effects). However vasoconstriction is also increased in splanchnic, portal, coronary, cerebral, peripheral, pulmonary, and intrahepatic vessels.
It decreases portal pressure in patients with portal hypertension. A notable undesirable effect is coronary artery constriction that may dispose patients with coronary artery disease to cardiac ischemia. This can be prevented with concurrent use of nitrates.
Its duration of action is approximately 3-6 hours. This agent's short half-life lessens the risk of acute water intoxication and makes it the ideal threatment of central DI in the acute situation. |
Adult Dose |
5-10 Units |
Pediatric Dose |
Safety and efficacy in children have not been established. |
Contraindications |
Avoid use in patients with documented hypersensitivity to this drug or related products, and in patients diagnosed with coronary artery disease. |
Interactions |
Lithium, epinephrine, demeclocycline, heparin, and alcohol may decrease the effects of vasopressin. Conversely, chlorpropamide, urea, fludrocortisone, and carbamazapine are known to potentiate its effects. |
Pregnancy |
B - Usually safe but benefits must outweigh the risks. |
Precautions |
Use with caution in patients diagnosed with cardiovascular disease, seizure disorders, nitrogen retention, asthma, or migraine. Excessive doses of this medication may result in hyponatremia. |
Drug Name |
DDAVP - It increases the cellular permeability of the collecting ducts. This results in the reabsorption of water by the kidneys. Its duration of action is approximately 12-24 h.
Administered once or twice a day. It has become the longterm treatment of choice of central DI. |
Adult Dose |
IV, SC: 2-4 mcg/d divided bid |
Pediatric Dose |
3 mo to 12 y: 5-30 mcg/d intranasally qd or divided bid. |
Contraindications |
Avoid use in patients with documented hypersensitivity to this medication or related products and those with platelet-type von Willebrand disease. |
Interactions |
Demeclocycline and lithium decrease desmopressin effects.
Fludrocortisone and chlopropamide increases desmopressin effects. |
Pregnancy |
B - Usually safe but benefits must outweigh the risks. |
Precautions |
Avoid overhydration in patients where the drug is being used for its hemostatic effects. |

FOLLOW-UP
Further Inpatient Care:
- Monitor electrolytes frequently.
- Insure that adequate calories are ingested.
Transfer:
- Patients who are fluid overloaded with hypernatremia may require hemodialysis. These patients should be transferred, if necessary, to a center with hemodialysis availability.
Deterrence/Prevention:
- Treatment of prevention of underlying cause
- Avoid preparing infant formulat at home and never add salt to any commercial infant formula
Complications:
- Acute hypernatremia often results in significant brain shrinkage causing mechanical traction of cerebral vasculature.
- Stretching of briding veins can result in subdural hemorrhages.
- Venous congestion can lead to venous or sinus thrombosis.
- Arterial stretching can result in subcortical hemorrhages and cerebral infarctions.
- Chronic duration (i.e., longer than two days) has a higher mortality
- Patients with a serum sodium greater than 180 mEq/L often have residual central nervous system damage.
Prognosis:
- Permanent neurologic sequelae have been reported in 10-30% of patients with acute hypernatremia.
Patient Education:
- Since elderly patients are often affected, education of care takers in ways to avoid dehydration may be useful.
- Patients with nephrogenic diabetes insipidus must avoid salt and drink large amounts of water.

MISCELLANEOUS
Medical/Legal Pitfalls:
- Overly aggressive hydration when hypernatremia is found.

BIBLIOGRAPHY
-
Berl T: Clinical disorders of water metabolism. Kidney Int 1976; 10: 117-32.
-
Finberg L, Luttell C, Redd H: Pathogenesis of lesions in the nervous system in hypernatremic states. Expermiental studies of goss anatomic chantes and alterations of chemical composition of the tissues. Pediatrics 1959; 184: 187.
-
Mahowald JM, Himmelstein DU: Hypernatremia in the elderly: relation to infection and mortality. J Am Geriatr Soc 1981; 29(4): 177-80.
-
Morris-Jones PH, Houston IB, Evans EC: Prognosis of the neurological complications of acute hypernatremia. Lancet 1962; 2: 1385.
-
Palevsky PM: Hypernatremia. Semin Nephrol 1998; 18(1): 20-30.
-
Robertson G, Aycinena P, Zerbe RL: Neurogenic disorders of osmoregulation. Am J Med 1982; 72(2): 339-53.
-
Tan MH: Changing factors in the etiology of diabetes insipidus. N S Med Bull 1971; 50: 153-60.
-
Teitelbaum I, Berl T: Watermetabolism in patients with electrolyte disorders. Seminars Nephrology 1984; 4: 354
|